[A18-51] Tofacitinib (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V
Last updated 03.12.2018
Project no.:
A18-51
Commission:
Commission awarded on 24.08.2018 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Skin and hair
Active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to a prior
Added benefit not proven for pretreatment with a conventional synthetic DMARD or with a biological DMARD
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A19-03 | Tofacitinib (psoriatic arthritis) - Addendum to Commission A18-51 | Commission completed |
| A18-28 | Tofacitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V (expiry of the decision) | Commission completed |
| A18-52 | Tofacitinib (Colitis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A17-18 | Tofacitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-165 | Tofacitinib (ankylosing spondylitis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-121 | Tofacitinib (jPsA and pJIA) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-115 | Tofacitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V (new scientific findings) | Commission completed |